Comparative Pharmacology
Head-to-head clinical analysis: HYPAQUE CYSTO versus RENOCAL 76.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYPAQUE CYSTO versus RENOCAL 76.
HYPAQUE-CYSTO vs RENOCAL-76
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HYPAQUE-CYSTO (diatrizoate meglumine) is a radiopaque contrast agent that absorbs x-rays, providing contrast in radiographic imaging. It acts as an iodinated contrast medium.
Contains iothalamate meglumine, an ionic high-osmolar contrast medium that absorbs X-rays, thereby enhancing vascular and tissue contrast during radiographic procedures. It functions by increasing the attenuation of X-rays in blood and tissues where it distributes.
Intravesical instillation: 100-300 mL of 30% solution for retrograde cystourethrography; single administration.
Intravenous: 50-100 mL of a 37% iodine-containing solution (approximately 14-28 g iodine) administered as a slow intravenous injection over 1-2 minutes, or as an intravenous infusion over 10-30 minutes, typically not exceeding 4.5 mL/kg body weight.
None Documented
None Documented
Terminal elimination half-life: 1.5–2.5 hours (normal renal function). Prolonged in renal impairment.
Terminal elimination half-life ranges from 1.2 to 2.5 hours in patients with normal renal function. In patients with severe renal impairment, half-life may be prolonged up to 20 hours.
Renal excretion via glomerular filtration: >95% unchanged within 24 hours. Fecal excretion: <5%.
Primarily renal excretion via glomerular filtration. Approximately 95% of administered dose is excreted unchanged in urine within 24 hours. Less than 5% undergoes biliary/fecal elimination.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent